AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial.

By P. LeWitt, A. Rezai, M. Leehey, Steven G. Ojemann, A. Feigin, S. Tatter. Lancet Neurology, 2011

624 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Neurology

View Paper: https://www.semanticscholar.org/paper/b38738dee11dbfa7ccc9e49de9050fed4c4b4656

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. P. Ali
2. Talebi Maedeh
3. Nouri Nayerossadat

Citations in the corpus

• Viral and nonviral delivery systems for gene delivery (2012, background): “These include successful treatment of patients with the retinal disease Leber congenital amaurosis,[175‐178] X‐linked SCID,[179] ADA–SCID,[180] adrenoleukodystrophy,[180] and Parkinson’s disease.[181]”